Literature DB >> 12583841

Neurocognitive dysfunction in children with neurofibromatosis type 1.

Tena L Rosser1, Roger J Packer.   

Abstract

The cognitive dysfunction associated with neurofibromatosis type 1 (NF1) is an intriguing aspect of this phenotypically heterogeneous genetic neurocutaneous disorder. A broad range of both nonverbal and verbal learning disabilities are evident in approximately 30% to 65% of children with NF1. Deficits in IQ, executive function, attention, and motor skills have also been documented. Current challenges lie in discovering the underlying multifactorial etiologies of the cognitive abnormalities found in NF1. Likely answers lie in neuroanatomic correlates as seen on neuroimaging as well as in molecular and genetic advances into the role of neurofibromin, the protein product of the NF1 gene. The development of NF1 animal models with learning and memory difficulties similar to those seen in humans demonstrates promising preliminary evidence that medical treatment of cognitive abnormalities may one day be possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583841     DOI: 10.1007/s11910-003-0064-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  47 in total

Review 1.  Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force.

Authors:  K N North; V Riccardi; C Samango-Sprouse; R Ferner; B Moore; E Legius; N Ratner; M B Denckla
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

2.  The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder.

Authors:  C W Koth; L E Cutting; M B Denckla
Journal:  Child Neuropsychol       Date:  2000-09       Impact factor: 2.500

3.  Neurofibromatosis: implications for learning and behavior.

Authors:  M J Eliason
Journal:  J Dev Behav Pediatr       Date:  1986-06       Impact factor: 2.225

4.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

5.  Neuropsychological deficits in adults with neurofibromatosis type 1.

Authors:  M E Zöller; B Rembeck; L Bäckman
Journal:  Acta Neurol Scand       Date:  1997-04       Impact factor: 3.209

6.  Neurofibromatosis type 1 presenting with hand dystonia.

Authors:  M Di Capua; M L Lispi; A Giannotti; D Longo; G Fariello
Journal:  J Child Neurol       Date:  2001-08       Impact factor: 1.987

7.  Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1.

Authors:  L E Cutting; C W Koth; C P Burnette; M T Abrams; W E Kaufmann; M B Denckla
Journal:  J Child Neurol       Date:  2000-03       Impact factor: 1.987

8.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain.

Authors:  D P DiPaolo; R A Zimmerman; L B Rorke; E H Zackai; L T Bilaniuk; A T Yachnis
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

9.  Children and adolescents with neurofibromatosis 1: a behavioral phenotype.

Authors:  C V Dilts; J C Carey; J C Kircher; R O Hoffman; D Creel; K Ward; E Clark; C O Leonard
Journal:  J Dev Behav Pediatr       Date:  1996-08       Impact factor: 2.225

10.  Neuropsychological profile of children with neurofibromatosis, brain tumor, or both.

Authors:  B D Moore; J L Ater; M N Needle; J Slopis; D R Copeland
Journal:  J Child Neurol       Date:  1994-10       Impact factor: 1.987

View more
  13 in total

Review 1.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

Review 2.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

3.  Cognitive profile of children with neurofibromatosis and reading disabilities.

Authors:  Laurie E Cutting; Terry M Levine
Journal:  Child Neuropsychol       Date:  2010       Impact factor: 2.500

4.  Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Authors:  Ivayla Apostolova; Dagmara Niedzielska; Thorsten Derlin; Eva J Koziolek; Holger Amthauer; Benedikt Salmen; Jens Pahnke; Winfried Brenner; Victor F Mautner; Ralph Buchert
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

Review 5.  Alternative splicing of the neurofibromatosis type I pre-mRNA.

Authors:  Victoria A Barron; Hua Lou
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

6.  Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.

Authors:  Jacquelyn A Brown; Kelly A Diggs-Andrews; Scott M Gianino; David H Gutmann
Journal:  Mol Cell Neurosci       Date:  2011-08-26       Impact factor: 4.314

7.  Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

Authors:  Jacquelyn A Brown; Ryan J Emnett; Crystal R White; Carla M Yuede; Sara B Conyers; Karen L O'Malley; David F Wozniak; David H Gutmann
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

8.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 9.  Neurofibromatosis type 1: new insights into neurocognitive issues.

Authors:  Maria T Acosta; Gerard A Gioia; Alcino J Silva
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

10.  Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway.

Authors:  Yi-Ling Lin; Ya-Ting Lei; Chen-Jei Hong; Yi-Ping Hsueh
Journal:  J Cell Biol       Date:  2007-06-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.